GF Fund Management
TRAX icon

GF Fund Management’s First Tracks Biotherapeutics TRAX Stock Holding History

GF Fund Management’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.6K Buy
750
+60
+9% +$2.34K ﹤0.01% 465
2026
Q2 		$13.9K Buy
+690
New +$12.9K ﹤0.01% 514

Other funds holding TRAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

GF Fund Management's TRAX Position: Q3 2026 in Review

GF Fund Management increased its First Tracks Biotherapeutics (TRAX) stake by 8.7% in Q3 2026, buying an estimated $2.34K and bringing the position to 750 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

GF Fund Management first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • GF Fund Management held 750 shares of First Tracks Biotherapeutics worth $26.6K as of Q3 2026.
  • GF Fund Management bought 60 First Tracks Biotherapeutics shares in Q3 2026, an estimated $2.34K.
  • First Tracks Biotherapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #465 holding.
  • GF Fund Management first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.